341031-54-7 Usage
Description
Sunitinib malate, also known as Sutent or SU11248, is a small molecule inhibitor of receptor tyrosine kinases (RTKs). It is a multi-targeted RTK inhibitor that targets VEGFR2 (Flk-1) and PDGFRβ with IC50 values of 80 nM and 2 nM, respectively, and also inhibits c-Kit. Sunitinib is available in 12.5-, 25-, and 50-mg capsules for oral administration and is used for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST) upon the failure of imatinib. It is a yellow solid and is marketed under the brand name Pfizer.
Uses
1. Used in Anticancer Applications:
Sunitinib malate is used as an anti-cancer drug for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). It works by inhibiting several receptor tyrosine kinases, including VEGFR2 (Flk-1), PDGFRβ, and c-Kit, which play a role in tumor growth and angiogenesis. This results in slowing tumor progression and inhibiting angiogenesis, making it particularly useful in highly vascularized cancers such as RCC and GIST.
2. Used in Drug Development:
Sunitinib malate is used as a multi-kinase inhibitor in the development of new antineoplastic drugs. Its ability to target several receptor tyrosine kinases makes it a promising candidate for the development of novel cancer therapies.
3. Used in Pharmaceutical Industry:
Sunitinib malate is used as a pharmaceutical compound in the production of cancer treatment medications. Its multi-targeted approach to inhibiting receptor tyrosine kinases has led to its widespread use in the development and formulation of cancer drugs.
Anticancer drug
Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the lookchem of Dai Xiongfeng.
Biological Activity
Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
Biochem/physiol Actions
Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.
References
1) Deeks et al. (2006), Sunitinib; Drugs, 66 2255
2) Guo et al. (2006), Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors; Mol. Cancer. Ther., 5 1007
3) O’Farrell et al. (2003), SU11248 is a novel FLT3 yrosine kinase with potent activity in vitro and in vivo; Blood, 101 3597
4) Roskoski et al. (2007), Sunitinib: a EGF and PDGF receptor protein kinase and angiogenesis inhibitor; Biochem. Biophys. Res. Commun., 356 323
Check Digit Verification of cas no
The CAS Registry Mumber 341031-54-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,1,0,3 and 1 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 341031-54:
(8*3)+(7*4)+(6*1)+(5*0)+(4*3)+(3*1)+(2*5)+(1*4)=87
87 % 10 = 7
So 341031-54-7 is a valid CAS Registry Number.
InChI:InChI=1/C23H30N4O2.C5H8O5/c1-6-27(7-2)11-10-24-23(29)21-15(4)20(25-16(21)5)13-18-17-12-14(3)8-9-19(17)26-22(18)28;6-3(5(9)10)1-2-4(7)8/h8-9,12-13,25H,6-7,10-11H2,1-5H3,(H,24,29)(H,26,28);3,6H,1-2H2,(H,7,8)(H,9,10)/b18-13-;/t;3-/m.0/s1
341031-54-7Relevant articles and documents
A high-purity malic acid lin's preparation method
-
, (2019/04/04)
The invention relates to a high-purity malic acid lin's preparation method, the method comprises the following steps: (1) the formula II compound as a starting material, the use of 1 - ethyl - (3 - dimethyl amino propyl) carbonylamino-carbodiimide hydrochloride with 1 - hydroxy benzotriazole as the condensing agent, under certain temperature and N, N diethylethylenediamine reaction to obtain compound III; (2) in the step (1) the reaction solution, between the step (1) the resulting reactant with 5 - fluoro indole - 2 - one reaction at certain temperature, to obtain compound IV; (3) in the step (2) of the reaction solution, so that the step (1) the resulting reactant with L - malic acid reaction at certain temperature, to obtain compound I; providing at least to a certain extent one of the solve the above technical problems or at least provide a useful commercial choice. The reaction route is operating time is short, simple operation, reaction system is stable, higher product yield, purity of the product is relatively high, it is suitable for industrial production.
PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF
-
, (2015/02/18)
The present invention relates to an improved process for the preparation of Sunitinb. The process involves the activation of 5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene) methyl)-2,4-dimethyl-1H-pyrrole-3carboxylic acid to corresponding suitable carboxylic acid activating group. The present invention also relates to novel acid addition salts of Sunitinb and preparation thereof.
PROCESS FOR THE DIRECT PREPARATION OF MALIC ACID SALT OF SUNITINIB
-
Paragraph 0014; 0015; 0016, (2013/05/22)
The present invention relates to a process for the direct preparation of malic acid salt of sunitinib.
